USAGE OF NAPHTHOPIZIL FOR TREATMENT OF DYSURIA IN BENIGN PROSTATIC HYPERPLASIA

摘要

PURPOSE: To prepare a therapeutic agent for dysuria in benign prostate hypertrophy comprising naftopidil or its salt as an active ingredient. CONSTITUTION: This therapeutic agent for dysuria comprises 1-(2- methoxyphenyl)-4-[3-(naphth-l-yl-oxy)-2-hydroxy-propyll-piperazine (naftopidil), having antihypertensive action, known to control anaphylactic reaction caused by dextran in a rat and represented by the formula as an active ingredient. The compound is especially orally applied and the daily dose thereof is 10-100mg and administered in a dose of 10-50mg at a time daily once or twice.